Cardiovascular Disease Prevalence Driving The Cardiac Resynchronization Therapy Market Growth: Powering Innovation and Expansion in the Cardiac Resynchronization Therapy Market by 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Cardiac Resynchronization Therapy Market Through 2025?
In recent times, the market size for cardiac resynchronization therapy (CRT) has seen impressive growth. Anticipated growth is projected from $6.29 billion in 2024 to $6.74 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historic period is due to several factors such as the increase in the elderly population, rising instances of heart failure, escalated investments in Research and Development for CRT device innovation, enhanced awareness regarding the benefits of the therapy, training programs for physicians, and the dynamics of a competitive landscape.

What's the Projected Size of the Global Cardiac Resynchronization Therapy Market by 2029?
Expect strong expansion in the cardiac resynchronization therapy market in the coming years, with predictions it will reach $8.77 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.8%. This projected increase over the forecast period is mainly due to an upsurge in heart failure and cardiac disorders, an aging population, a higher rate of cardiovascular diseases, the necessity for CRT therapy, advancements in pacemakers and defibrillator treatment, as well as a raised awareness of CRT therapy. Furthermore, trends to watch for in this forecast period include the preference for CRT-D devices over conventional pacemakers, the incorporation of top-end technologies as well as artificial intelligence, CRT therapy expansion, and the employment of machine learning.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiac-resynchronization-therapy-global-market-report

Top Growth Drivers in the Cardiac Resynchronization Therapy Industry: What's Accelerating the Market?
The cardiac resynchronization therapy market's expansion is projected to be fueled by an increase in cardiovascular diseases. Heart and blood vessel ailments are encapsulated under the terminology cardiovascular diseases (CVD). The elderly population's growth, unhealthy lifestyles, rising tobacco usage, sedentary conduct, and poor diets contribute to the increase in these conditions. Cardiac resynchronization therapy (CRT) proves beneficial in treating cardiovascular issues, such as heart failure by enhancing the synchronization of heart contractions via electronic stimuli. Data from the Minnesota Department of Health revealed that about 30% of Minnesota's adults, approximately 1.4 million individuals, were diagnosed with high blood pressure in 2023 and in 2022, nearly 28% of all deaths were linked to hypertensive diseases. Consequently, the rise in cardiovascular diseases is escalating the growth of the cardiac resynchronization therapy market. Surging health care expenditure is expected to contribute to the growth of the cardiac resynchronization therapy market. Health care expenditure encompasses the total money spent on health care products and services within a certain time frame, generally at a national or institutional level. Investing in health care could stimulate research and innovation in cardiac resynchronization therapy, leading to technological advancements, increased access to therapy, and a more holistic approach to individual's health and health care systems. The UK's Office for National Statistics showed a 9.4% nominal and 9.7% real growth in health care spending in 2023. The total health care cost in the UK was $367.25 billion (£280.7 billion) in 2021, with $51.84 billion (£39.6 billion) spent on pharmaceuticals. Statistics published by Cross River Therapy indicated that U.S. pharmaceuticals brought in $550 billion and Americans expended $576.9 billion on medicine in 2021, with a projected surge to $605-$635 billion by 2025. This rise in health care spending is propelling the growth of the cardiac resynchronization therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15531&type=smp

What Trends Will Shape the Cardiac Resynchronization Therapy Market Through 2029 and Beyond?
Primarily focused on creating implantable devices, large firms in the cardiac resynchronization therapy market are aiming to elevate treatment outcomes for people suffering from heart failure. These implantable tools utilized in cardiac resynchronization therapy (CRT) enhance heart pumping efficacy and help control heart failure symptoms by orchestrating the contractions of the heart's ventricles. For instance, MicroPort Scientific Corporation, a medical device establishment based in China, introduced the GALI SonR cardiac resynchronization therapy and defibrillation tool (CRT-D), together with Navigo 4LV left ventricular pacing leads in Japan in February 2024. This is the only and inaugural CRT hemodynamic sensor intended to automatically fine-tune patients on a weekly basis, most importantly when the patient is active, encouraging real-world optimization. The clinically validated SonR algorithm reduces the risk of heart failure hospitalization by 35% and also guarantees the health and safety of the CRT-D patient.

What Are the Main Segments in the Cardiac Resynchronization Therapy Market?
The cardiac resynchronization therapy market covered in this report is segmented -

1) By Type: Cardiac Resynchronization Therapy (CRT)-Defibrillator, Cardiac Resynchronization Therapy (CRT)-Pacemaker
2) By Age: Below 44 Years, 45-64 Years, 65-84 Years, Above 85 Years
3) By End-Use: Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers

Subsegments:
1) By Cardiac Resynchronization Therapy (CRT)-Defibrillator: Single-Chamber CRT-D, Dual-Chamber CRT-D, Triple-Chamber CRT-D, Bi-Ventricular CRT-D
2) By Cardiac Resynchronization Therapy (CRT)-Pacemaker: Single-Chamber CRT-P, Dual-Chamber CRT-P, Triple-Chamber CRT-P, Bi-Ventricular CRT-P

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15531&type=smp

Which Top Companies are Driving Growth in the Cardiac Resynchronization Therapy Market?
Major companies operating in the cardiac resynchronization therapy market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, Lepu Medical Technology (Beijing) Co. Ltd., Integer Holdings Corporation, Merit Medical Systems Inc., LivaNova PLC, MicroPort Scientific Corporation, Sorin Group, Berlin Heart GmbH, EBR Systems Inc., Corvia Medical Inc., Recor Medical, Jarvik Heart Inc., Cardiac Dimensions Inc., Farapulse Inc., Osypka Medical GmbH, Japan Medical Device Corporation, Imricor Medical Systems Inc., Vascular Dynamics Inc., Svelte Medical Systems, Aleva Neurotherapeutics, BioSig Technologies Inc.

Which Regions Will Dominate the Cardiac Resynchronization Therapy Market Through 2029?
North America was the largest region in the cardiac resynchronization therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15531

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.